December 10, 2021 5:44pm

The Biostage (BSTG) Chronicles: Friday closed up +$0.20 with 9,669 shares traded. The share price was down -$0.35 with 1,366 shares traded throughout the session and suddenly at around 2 p.m. 8,333 share buy was executed? “Pumped and Promoted”; does the pattern of months and months of trading volume express a time for the SEC to take a closer look?

Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public markets investor to a journalist; it is that your life and your bank account are largely tied to your questioning of price movements and targets.

 

The Dow closed UP +216.30 points (+0.60%); the S&P closed UP +44.57 points (+0.95%) while the Nasdaq closed UP +113.23 points (+0.73%)

 

Henry’omics:

Indexes rose on Friday, despite inflation hitting a 39-year high.

Friday’s moves came after the major averages ended the regular trading session lower, each snapping a three-day win streak.

The Inflation news was as bad as expected. What it means for the Fed and Biden….

  • The fastest rise in consumer prices in nearly four decades is paving the way for the Federal Reserve to move more quickly to tighten monetary policy. It’s also presenting a major headache for the Biden White House and likely … derailing its goals of passing a multitrillion-dollar social-spending package before the end of the year. (Meg Cassella, Barron’s

The Dow is up 3.8%, the S&P 500 +3.4% and Nasdaq 3.1%, at the end of this week.

 

Economic data Docket: The Labor Department's report showed U.S. consumer prices accelerated 6.8% in the 12 months through November, their highest level since 1982, as the cost of goods and services rose broadly amid supply constraints.

  • The so-called core consumer price index (CPI) excludes food and energy prices jumped 4.9% on a year-on-year basis after gaining 4.6% in October.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Friday opened positive at 26 ups/7 downs, 1 flat and 1 acquired, flipped negative at the mid-day at 10/24 and 1 acquired, ending with a negative close of 8 up/25 downs, 1 flat and 1 acquired;
  • Thursday opened negative at 4 ups/20 downs, 1 flat and 1 acquired, stayed positive at the mid-day at 3/30, 1 flat and 1 acquired, ending with a negative close of 0 up/33 downs, 1 flat and 1 acquired;
  • Wednesday opened positive at 16 ups/13 downs, 5 flats and 1 acquired, stayed positive at the mid-day at 26/6, 2 flats and 1 acquired, ending with a positive close of 24 up/7 downs, 3 flats and 1 acquired;
  • Tuesday opened positive at 28 ups/4 downs, 2 flats and 1 acquired, stayed positive at the mid-day at 31/2, 1 flat and 1 acquired, ending with a positive close of 29 up/4 downs, 1 flat and 1 acquired;
  • Monday opened negative at 13 ups/21 downs and 1 acquired, flipped positive at the mid-day at 23/11, 1 flat and 1 acquired, ending with a positive close of 25/9 and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “a negative indication had warned me that an acknowledged drop continued to lurk. Especially a very weak aftermarket after the Nasdaq registered a third day of gains” … https://www.regmedinvestors.com/articles/12218

 

 

The Biostage (BSTG) Chronicles: Friday closed up +$0.20 with 9,669 shares traded (month average = 2,798), Thursday closed $0.00 with 26 shares traded, Wednesday closed down -$0.34 with 160 shares traded, Tuesday closed down -$0.20 with 2,965 shares traded and last Monday closed +$0.21 to $3.21 with 6,466 shares traded, Friday closed flat with 0 shares traded, and last Thursday closed up +$0.07 with 3,527 shares traded

  • The share price was down -$0.35 with 1,366 shares traded throughout the session and suddenly at around 2 p.m. 8,333 share buy was executed?
  • “Pumped and Promoted”; does the pattern of months and months of trading volume express a time for the SEC to take a closer look?

 

Note: A new coronavirus variant with a large number of mutations is raising concerns as even as Omicron cases caused mild illness in the vaccinated. The BIG question, is it's unclear whether vaccinations or prior Covid infection provide substantial protection against the omicron variant, which has now been found in eighteen (18) l U.S. states.

 

Key Metric - volume

Sector volume LOW with 2 of the 8-upside having higher than the 3-month average volume with LOW volume of 7 of 25-downside having higher than the 3-month average volume;

 

Jumping with share pricing momentum (8 of 8):

  • ReNeuron (RENE.L -$2.00 after Thursday’s -$6.00),
  • Intellia Therapeutics (NTLA +$1.96 after Thursday's -$4.38 after Wednesday’s -$0.67, Tuesday’s +$16.34 and Monday’s -$0.27),
  • Alnylam Pharmaceuticals (ALNY +$1.18 after Thursday’s -$4.45, Wednesday’s -$3.36, Tuesday’s +$3.28 and Monday’s +$5.64),
  • Regenxbio (RGNX +$0.44),
  • uniQure NV (QURE +$0.22),
  • Biostage (BSTG+$0.20),
  • Chinook Therapeutics (KDNY +$0.20),
  • Pluristem (PSTI +$0.02),

Hammered in today’s market (10 of 25):

  • Fate Therapeutics (FATE -$4.09 after Thursday’s -$2.71, Wednesday’s +$1.37, Tuesday’s +$6.75 and Monday’s -$0.16),
  • CRISPR Therapeutics (CRSP -$1.83 after Thursday’s -$3.95, Wednesday’s +$1.02, Tuesday’s +$7.27 and Monday’s +$1.03),
  • Editas Medicine (EDIT -$1.52),
  • Global Blood Therapeutics (GBT -$1.36),
  • Ionis Pharmaceuticals (IONS -$1.93 after Wednesday’s +$1.64, Tuesday’s +$3.07 and Monday’s +$1.11),
  • Ionis Pharmaceuticals (IONS -$0.81 after Thursday’s -$1.93, Wednesday’s +$1.64, Tuesday’s +$3.07 and Monday’s +$1.11),
  • Vericel (VCEL -$0.62 after Thursday’s -$2.11, Wednesday’s +$0.94, Tuesday’s +$2.24 and Monday’s +$1.81),
  • Ultragenyx (RARE -$0.59 after Thursday’s -$2.52, Wednesday’s -$3.43, Tuesday’s +$5.55 and Monday’s +$2.88),
  • bluebird bio (BLUE -$0.42),
  • Sangamo Therapeutics (SGMO -$0.41),

Closing Flat:

  • 1 – Bellicum Pharmaceuticals (BLCM) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB closed down -1.52% and XBI closed down -1.67%
  • Thursday, the IBB closed down -2.07% and XBI closed down -4.21%
  • Wednesday, the IBB closed up +1.13% and XBI closed up +1.43%
  • Tuesday, the IBB closed up +3.92% and XBI closed up +.98%
  • Monday the IBB closed down -2.01% and XBI closed up +0.15%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -2.89 points or -13.39 % at 18.69
  • Thursday was up +1.68 points or +8.44% at 21.58
  • Wednesday was down 1.99- points or -9.09% at 19.90
  • Tuesday was down -5.29 points or -19.46% at 21.89
  • Monday was down -2.97 points or -9.68% at 27.70

 

December, the second month of Q4/21:

Friday closed negative with 8 incliner, 25 decliners, 1 flat and 1 acquired

Thursday closed negative with 0 incliners, 33 decliners, 1 flat and 1 acquired

Wednesday closed positive with 24 incliners, 7 decliners, 3 flats and 1 acquired

Tuesday closed positive with 29 incliner, 4 decliners, 1 flat and 1 acquired

Monday (12/6) closed positive with 25 incliner, 9 decliners and 1 acquired

 

The BOTTOM LINE:  Knew it – the cratering came and then fell again ... 

Yesterday, the session to “show me the money” … hit the nail on its head.

Tread lightly, tax selling is upon us!

In any case, I have continued to write … don’t ramp exposure at the current levels.

Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.